PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'University of Southampton, Southampton, Hampshire, UK. G.O.Griffiths@soton.ac.uk.\', \'Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.\', \'Lancaster University and University of Cambridge, Lancaster, Lancashire, UK.\', \'Southampton CTU, University of Southampton, Southampton, Hampshire, UK.\', \'University of Liverpool, Liverpool, UK.\', \'Medidata Solutions, London, UK.\', \'Cancer Research UK Centre for Drug Development, London, UK.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1186/s13063-020-04473-1
?:doi
?:hasPublicationType
?:journal
  • Trials
is ?:pmid of
?:pmid
?:pmid
  • 32560744
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.291
?:rankingScore_hIndex
  • 57
?:title
  • AGILE-ACCORD: A Randomized, Multicentre, Seamless, Adaptive Phase I/II Platform Study to Determine the Optimal Dose, Safety and Efficacy of Multiple Candidate Agents for the Treatment of COVID-19: A structured summary of a study protocol for a randomised platform trial.
?:type
?:year
  • 2020

Metadata

Anon_0  
expand all